Outpace Bio
Outpace Bio develops AI-powered protein design technologies to create engineered cell therapies for cancer treatment. Its platform programs cells to improve potency, specificity, persistence, and safety, aiming to make cell therapies effective, safe, and scalable across diverse cancer indications. The organization’s mission is to cure cancer by overcoming biological barriers through advanced cellular engineering.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2020
- Type
- Corporation Seattle business license
- Employees
- 74
- Registered name
- Outpace Bio Inc Seattle business license
- Stage
- Series A
- Members see funding amounts. .
Is this your organization? Claim it
Fred Hutch-Led Synthesize Bio Raises $10M to Accelerate Drug Discovery Using AI Gene Expression Model
Seattle-based Synthesize Bio, led by Fred Hutchinson Cancer Center researchers, raised $10 million from Madrona to accelerate drug discovery using their AI model GEM-1, which predicts gene expression outcomes with lab-level accuracy. The startup aims to reduce drug development time and costs by simulating hypothetical lab experiments with generative genomics.
Seattle Biotech Tune Therapeutics Raises $175M to Advance Epigenetic Editing Trials for Chronic Hepatitis B
Seattle-based biotech startup Tune Therapeutics raised $175 million to support clinical trials of its epigenetic editing treatments for chronic Hepatitis B. The funding will aid development of therapies that control gene expression without altering DNA, leveraging technology developed at Duke University.
University of Washington Launches Vilya with $50 Million to Develop Membrane-Permeable Peptide Drugs
University of Washington researchers developed custom peptides that penetrate cell membranes, enabling a new class of drugs with combined benefits of small molecules and protein therapeutics. They founded Vilya, backed by $50 million from Arch Venture Partners, to commercialize this drug platform described in Cell.
People
See all 5-
Marc Lajoie Executive Officer, Director, Promoter, Co-founder & Chief Executive Officer
-
Scott Boyken Executive Officer, Director, Promoter, Co-founder & Chief Innovation Officer
-
Aaron Foster Executive, Executive Officer, Chief Scientific Officer
Online
Questions about Outpace Bio
What is Outpace Bio?
outpacebio.com
Who are the people behind Outpace Bio?
Marc Lajoie is co-founder and chief executive officer of Outpace Bio, and Scott Boyken is co-founder and chief innovation officer. Aaron Foster is chief scientific officer, Charity Scripture is chief development officer, and Eric Soller is chief business officer.
Who invested in Outpace Bio, and how much has it raised?
Members of Seattle Flow see Outpace Bio's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Outpace Bio based?
Outpace Bio is based in Seattle, Washington, US.
When was Outpace Bio founded?
Outpace Bio was founded in 2020.
How many people work at Outpace Bio?
Outpace Bio has 74 employees.